{
    "clinical_study": {
        "@rank": "50118", 
        "acronym": "PREDICTIVE\u2122", 
        "arm_group": {
            "arm_group_label": "Insulin detemir", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in North America. The aim of this trial is to evaluate the safety of\n      insulin detemir for the treatment of diabetes."
        }, 
        "brief_title": "Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with type 1 or type 2 diabetes\n\n          -  Using a basal/bolus insulin regimen\n\n        Exclusion Criteria:\n\n          -  Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude,\n             inability to return for the final visit\n\n          -  Subjects who previously enrolled in this study\n\n          -  Subjects with a hypersensitivity to insulin detemir or to any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2287", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709929", 
            "org_study_id": "NN304-1713"
        }, 
        "intervention": {
            "arm_group_label": "Insulin detemir", 
            "description": "Administered subcutaneously (s.c., under the skin). Dose individually adjusted.", 
            "intervention_name": "insulin detemir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 16, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Mississauga", 
                    "country": "Canada", 
                    "zip": "L4W 4XI"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre, Open Label, Nonrandomised, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Novo Nordisk Canada Inc.", 
            "last_name": "Angele Mongol", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709929"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of adverse events (all and serious)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Number of all hypoglycaemic events", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Change in weight", 
                "safety_issue": "No"
            }, 
            {
                "measure": "HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Treatment satisfaction as assessed by Insulin Treatment Satisfaction Questionnaire (ITSQ-22)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2005", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}